Search results
Results from the WOW.Com Content Network
Acuitas Therapeutics Inc. is a Canadian biotechnology company based in Vancouver, British Columbia. The company was established in February 2009 to specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticle (LNP) technology, a key component of the mRNA vaccines deployed for COVID-19. [1] [2]
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
The biotech recently became a commercial-stage company. ... Its price in the U.S. is $2.2 million. Its total addressable market includes about 35,000 patients in the U.S. and Europe and an ...
*Stock Advisor returns as of May 13, 2024. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals.
The S&P/TSX 60 Index is a stock market index of 60 large companies listed on the Toronto Stock Exchange. Launched on December 30, 1998 by the Canadian S&P Index Committee, [ 1 ] a unit of S&P Dow Jones Indices , the index has components across nine sectors of the Canadian economy.
The S&P/TSX Composite Index is the benchmark Canadian stock market index representing roughly 70% of the total market capitalization on the Toronto Stock Exchange (TSX). Having replaced the TSE 300 Composite Index on May 1, 2002, [1] as of September 20, 2021 the S&P/TSX Composite Index comprises 237 of the 3,451 companies listed on the TSX. [2]
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. [ 2 ] [ 3 ] The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom.